Trypanosoma Vaccine

Trypanosoma cruzi proteinase protects against trypanosomiasis

Published in Vaccine Weekly, November 6th, 2002

by Maria G. Essig, MS, ELS, senior medical writer - The major proteinase of Trypanosoma cruzi, cruzipain, showed promise as a vaccine component to prevent trypanosomiasis, according to a report in Infection and Immunity.

Anita R. Schnapp and colleagues at St. Louis University and Washington University in St. Louis, explained that they chose cruzipain for testing because it "is expressed by all developmental forms and strains of the parasite and stimulates potent humoral and cellular immune responses during infection in both humans and mice."

The investigators created a line of CD4+ T lymphocytes that were reactive to cruzipain and...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2002-11-06)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry